Private equity firm Advent International and Singapore wealth fund GIC have agreed to buy drugmaker Swedish Orphan Biovitrum AB for 69 billion kronor ($8 billion) in the largest buyout of a Nordic company in more than five years.
To read the entire story, you must be logged in.
Please log in now or register with us.
